Fresenius SE & Co. KGaA (SWX:FRE)

Market Cap	22.62B +5.9%
Revenue (ttm)	21.30B +4.2%
Net Income	1.18B +168.4%
EPS	2.09 +168.4%
Shares Out	n/a
PE Ratio	19.22
Forward PE	11.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	n/a
Open	53.05
Previous Close	53.05
Day's Range	n/a
52-Week Range	40.61 - 53.05
Beta	n/a
RSI	n/a
Earnings Date	Mar 25, 2026

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod...

• Industry: Medical - Specialties
• Sector: Healthcare
• Founded: 1912
• Employees: 155,186
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: FRE

Financial Performance

In 2025, Fresenius SE & Co. KGaA's revenue was 22.87 billion, an increase of 4.19% compared to the previous year's 21.95 billion. Earnings were 1.26 billion, an increase of 168.37%.

Financial numbers in EUR